Phase 2 trial of sitagliptin as a DPP-4 inhibitor for Grade 4 gliomas.

This study evaluates sitagliptin given before and after surgery in resectable Grade 4 glioma patients at Case Comprehensive Cancer Center in Cleveland. It is designed to assess if targeting MDSCs via DPP-4 inhibition can enhance immune responses in a novel, repurposed application of an FDA-approved diabetes drug.